消毒散联合干扰素对宫颈HR-HPV感染患者效果及HR-HPV的影响
|
摘要
目的探讨消毒散联合干扰素对宫颈HR-HPV感染患者效果及HR-HPV的影响。方法选取2016年3月～2017年3月在我院接受治疗的宫颈HR-HPV感染患者68例,按照随机数字表法分为研究组和对照组。对照组应用消毒散进行治疗,研究组在对照组基础上联合应用干扰素治疗,对比两组患者的治疗效果、HPV转阴率及TCT变化情况。结果研究组患者的治疗有效率显著高于对照组(P<0.05);治疗3个月、6个月、12个月后研究组患者的HPV转阴率均显著高于对照组(P<0.05);治疗3个月、6个月、12个月后研究组的TCT未见HILM率显著高于对照组(P<0.05)。结论宫颈HR-HPV感染患者行消毒散联合干扰素治疗效果显著,不仅能够有效提高患者的HPV转阴率,还可以改善患者的TCT情况,值得在临床上进一步推广应用。
Objective To investigate the effect of disinfection powder combined with interferon on the effect of HRHPV in patients with cervical HR-HPV infection. Methods A total of 68 patients with cervical HR-HPV infection who were treated in our hospital from March 2016 to March 2017 were enrolled. The patients were divided into study group and control group according to the random number table method. The control group was treated with disinfectant powder. The study group was treated with interferon on the basis of the treatment of the control group. The treatment effect,HPV negative rate and TCT change were compared between the two groups. Results The effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05). The HPV negative rate in the study group was significantly higher than that in the control group at 3 months, 6 months, and 12 months after treatment(P<0.05). The HILM rate of TCT in the study group was significantly higher than that in the control group at 3 months,6 months, and 12 months after treatment(P<0.05). Conclusion Disinfection powder combined with interferon in patients with cervical HR-HPV infection has significant difference, which is not only effective in improving the HPV negative rate, but also improving the patient's TCT.It is worthy of further clinical application.
Objective To investigate the effect of disinfection powder combined with interferon on the effect of HRHPV in patients with cervical HR-HPV infection. Methods A total of 68 patients with cervical HR-HPV infection who were treated in our hospital from March 2016 to March 2017 were enrolled. The patients were divided into study group and control group according to the random number table method. The control group was treated with disinfectant powder. The study group was treated with interferon on the basis of the treatment of the control group. The treatment effect,HPV negative rate and TCT change were compared between the two groups. Results The effective rate of treatment in the study group was significantly higher than that in the control group(P<0.05). The HPV negative rate in the study group was significantly higher than that in the control group at 3 months, 6 months, and 12 months after treatment(P<0.05). The HILM rate of TCT in the study group was significantly higher than that in the control group at 3 months,6 months, and 12 months after treatment(P<0.05). Conclusion Disinfection powder combined with interferon in patients with cervical HR-HPV infection has significant difference, which is not only effective in improving the HPV negative rate, but also improving the patient's TCT.It is worthy of further clinical application.
引文
[1]李翡,郑伟,朱虹丽,等.凤香载体栓联合奥平栓治疗宫颈HR-HPV感染疗效观察[J].辽宁中医杂志,2017,12(8):1649-1650.
[2]朱丽娟,周树林,江希萍.重组人干扰素α2b联合洁悠神对宫颈持续HPV感染患者端粒酶与HPV16/18 E6蛋白表达的影响[J].中国现代医学杂志,2017,23(25):23-27.
[3]张琳,郑鹏涛,刘义彬,等.高级别宫颈上皮内瘤变患者HR-HPV持续感染情况及影响因素分析[J].山东医药,2016,56(42):77-79.
[4]董丽花,徐永萍,范明华.膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察[J].中国药房,2017,28(2):233-236.
[5]王雁,孔为民,吴玉梅,等.宫颈冷刀锥切术和全子宫切除术对CINⅢ合并高危型HPV阳性患者治疗结局的影响[J].实用妇产科杂志,2016,32(2):122-125.
[6]胡莉琴,赖晓莉,李梅,等.重组人干扰素α-2b凝胶对慢性宫颈炎合并HPV感染患者炎症因子及免疫功能的影响[J].中国地方病防治杂志,2016,34(9):1068-1068.
[7]胡利丹,卢雪映,胡月南,等.宫颈病变患者HPV感染的流行病学调查及危险因素分析[J].中华医院感染学杂志,2017,27(22):5212-5215.
[8]张玲,曲芃芃.HR-HPV持续感染宫颈局部8种细胞因子变化的研究[J].中国妇产科临床杂志,2018,36(1):6-8.
[9]邢亚萍,宋晓霞,丁胭脂,等.子宫颈低级别鳞状上皮内病变与HR-HPV的关系[J].临床与实验病理学杂志,2017,42(12):1356-1359.
[10]Wu Z,Qin Y,Yu L,et al.Association between hu man papillomavirus(HPV)16,HPV18,and other HR-HPVviral load and the histological classification of cervical lesions:Results from a large-scale cross-sectional study[J].Journal of Medical Virology,2017,89(3):535-541.
[11]张涛,毛世华,唐良萏.宫颈上皮内瘤变及早期宫颈癌组织中P16、HPVL-1壳蛋白的表达及与HR-HPV载量相关性研究[J].实用妇产科杂志,2016,32(7):536-539.
[12]吴晓燕,谷冀晖.合并高危型HPV感染的宫颈癌患者肿瘤组织FHIT、C-myc蛋白表达观察[J].山东医药,2017,57(15):91-93.
[13]文政芳,王世进,杨君,等.高危型人乳头状瘤病毒感染宫颈癌患者病变组织与细胞株中TLR4/iNOS通路分子的表达[J].中华医院感染学杂志,2016,26(18):4198-4200.
[14]Ahmad A,Raish M,Shahid M,et al.The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer[J].Cancer Biomarkers,2017,19(4):1-7.
[15]李美霞,薛慧英,陈健萍,等.重组人干扰素α-2b联合保妇康栓对人乳头状瘤病毒感染患者疗效及免疫功能的影响[J].中华医院感染学杂志,2016,26(14):3296-3298.
[16]邱胜凤.消疣汤联合干扰素α-2b凝胶治疗HR-HPV感染宫颈病变患者的效果[J].医疗装备,2016,29(24):105-106.
[17]杨彩虹,孟焕然,万颖,等.膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变合并HPV高危型感染的临床疗效[J].癌症进展,2016,14(12):1249-1251.
[18]马小磊,张雪艳,范蓉.重组人干扰素α2b阴道泡腾胶囊联合宫颈电切术治疗宫颈上皮内瘤样病变伴高危型HPV感染的临床效果[J].中国妇幼保健,2017,32(9):2011-2014.
[19]宋小琳.LEEP术联合干扰素治疗HR-HPV持续感染的围绝经期CIN的临床分析[J].中国生育健康杂志,2017,8(1):64-66.
[20]黄文娟.乳杆菌活菌胶囊、干扰素α-2b栓联合LEEP术治疗CIN伴HR-HPV的疗效研究[J].中国微生态学杂志,2017,29(5):587-590.
[2]朱丽娟,周树林,江希萍.重组人干扰素α2b联合洁悠神对宫颈持续HPV感染患者端粒酶与HPV16/18 E6蛋白表达的影响[J].中国现代医学杂志,2017,23(25):23-27.
[3]张琳,郑鹏涛,刘义彬,等.高级别宫颈上皮内瘤变患者HR-HPV持续感染情况及影响因素分析[J].山东医药,2016,56(42):77-79.
[4]董丽花,徐永萍,范明华.膦甲酸钠联合重组人干扰素α2b治疗宫颈HPV持续感染的疗效观察[J].中国药房,2017,28(2):233-236.
[5]王雁,孔为民,吴玉梅,等.宫颈冷刀锥切术和全子宫切除术对CINⅢ合并高危型HPV阳性患者治疗结局的影响[J].实用妇产科杂志,2016,32(2):122-125.
[6]胡莉琴,赖晓莉,李梅,等.重组人干扰素α-2b凝胶对慢性宫颈炎合并HPV感染患者炎症因子及免疫功能的影响[J].中国地方病防治杂志,2016,34(9):1068-1068.
[7]胡利丹,卢雪映,胡月南,等.宫颈病变患者HPV感染的流行病学调查及危险因素分析[J].中华医院感染学杂志,2017,27(22):5212-5215.
[8]张玲,曲芃芃.HR-HPV持续感染宫颈局部8种细胞因子变化的研究[J].中国妇产科临床杂志,2018,36(1):6-8.
[9]邢亚萍,宋晓霞,丁胭脂,等.子宫颈低级别鳞状上皮内病变与HR-HPV的关系[J].临床与实验病理学杂志,2017,42(12):1356-1359.
[10]Wu Z,Qin Y,Yu L,et al.Association between hu man papillomavirus(HPV)16,HPV18,and other HR-HPVviral load and the histological classification of cervical lesions:Results from a large-scale cross-sectional study[J].Journal of Medical Virology,2017,89(3):535-541.
[11]张涛,毛世华,唐良萏.宫颈上皮内瘤变及早期宫颈癌组织中P16、HPVL-1壳蛋白的表达及与HR-HPV载量相关性研究[J].实用妇产科杂志,2016,32(7):536-539.
[12]吴晓燕,谷冀晖.合并高危型HPV感染的宫颈癌患者肿瘤组织FHIT、C-myc蛋白表达观察[J].山东医药,2017,57(15):91-93.
[13]文政芳,王世进,杨君,等.高危型人乳头状瘤病毒感染宫颈癌患者病变组织与细胞株中TLR4/iNOS通路分子的表达[J].中华医院感染学杂志,2016,26(18):4198-4200.
[14]Ahmad A,Raish M,Shahid M,et al.The synergic effect of HPV infection and epigenetic anomaly of the p16 gene in the development of cervical cancer[J].Cancer Biomarkers,2017,19(4):1-7.
[15]李美霞,薛慧英,陈健萍,等.重组人干扰素α-2b联合保妇康栓对人乳头状瘤病毒感染患者疗效及免疫功能的影响[J].中华医院感染学杂志,2016,26(14):3296-3298.
[16]邱胜凤.消疣汤联合干扰素α-2b凝胶治疗HR-HPV感染宫颈病变患者的效果[J].医疗装备,2016,29(24):105-106.
[17]杨彩虹,孟焕然,万颖,等.膦甲酸钠氯化钠联合重组人干扰素α-2b栓治疗宫颈癌前病变合并HPV高危型感染的临床疗效[J].癌症进展,2016,14(12):1249-1251.
[18]马小磊,张雪艳,范蓉.重组人干扰素α2b阴道泡腾胶囊联合宫颈电切术治疗宫颈上皮内瘤样病变伴高危型HPV感染的临床效果[J].中国妇幼保健,2017,32(9):2011-2014.
[19]宋小琳.LEEP术联合干扰素治疗HR-HPV持续感染的围绝经期CIN的临床分析[J].中国生育健康杂志,2017,8(1):64-66.
[20]黄文娟.乳杆菌活菌胶囊、干扰素α-2b栓联合LEEP术治疗CIN伴HR-HPV的疗效研究[J].中国微生态学杂志,2017,29(5):587-590.